Behandlingsrelaterede venøse tromboemboliske hændelser er rapporteret hos 7 af patienterne (1, 9%), der fik SUTENT i fase 3 behandlingsnaiv mRCC- undersøgelse og hos 4 af patienterne (2%) i de 2 cytokin- refraktære mRCC- undersøgelser.
Seven patients (1.9%) receiving SUTENT in the phase 3 treatment-naïve MRCC study and four patients (2%) on the two cytokine-refractory MRCC studies had treatment-related venous thromboembolic events reported.